Lymphoplasmacytic Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Lymphoplasmacytic Lymphoma

MalaCards integrated aliases for Lymphoplasmacytic Lymphoma:

Name: Lymphoplasmacytic Lymphoma 12 36 15 37
Malignant Lymphoma - Lymphoplasmacytic 71
Waldenstrom Macroglobulinemia 71


External Ids:

Disease Ontology 12 DOID:0050747
KEGG 36 H00011
UMLS 71 C0024419 C0334633

Summaries for Lymphoplasmacytic Lymphoma

KEGG : 36 Lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) is a non-Hodgkin lymphoma (NHL) subtype characterized by small B-lymphocytes, plasmacytoid lymphocytes, and plasma cells, usually involving bone marrow, lymph nodes, and the spleen. WM can be distinguished clinically from LPL on the basis of a detectable monoclonal (IgM) immunoglobulin spike in serum. In the general population, LPL/WM is a very rare disease, accounting for only 1%-2% of all hematologic malignancies, reflected in an incidence rate of 3-4 cases per million people per year. The t(9;14)(p13;q32) is present in near 50% of cases of LPL. This chromosomal translocation involves a junction between 9p13 and the switch micro region of the Ig heavy chain locus on 14q32. The 9p13 breakpoint contains the PAX-5 gene which encodes a B-cell specific transcription factor involved in the control of B-cell proliferation and differentiation. The translocation causes the juxtaposition of the PAX-5 gene to the IgH locus in the opposite direction of transcription, resulting in an 11-fold over-expression of PAX-5 mRNA.

MalaCards based summary : Lymphoplasmacytic Lymphoma, also known as malignant lymphoma - lymphoplasmacytic, is related to waldenstroem's macroglobulinemia and macroglobulinemia. An important gene associated with Lymphoplasmacytic Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

Wikipedia : 74 Waldenström macroglobulinemia (WM), is a type of cancer affecting two types of B cells:... more...

Related Diseases for Lymphoplasmacytic Lymphoma

Diseases related to Lymphoplasmacytic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 waldenstroem's macroglobulinemia 33.9 MYD88 MAG CXCR4 CD40LG
2 macroglobulinemia 31.6 PAX5 MYD88 CXCR4 CXCL12 CD40LG
3 gamma heavy chain disease 30.8 MYD88 CD40LG
4 heavy chain disease 30.8 MYD88 CD40LG
5 lymphoma 30.8 PAX5 MYD88 MS4A1 IRF4 CXCR4 CD40LG
6 marginal zone b-cell lymphoma 30.7 PAX5 MYD88 IRF4 CD40LG CCND1
7 bone lymphoma 30.6 PAX5 IRF4
8 lymphoma, hodgkin, classic 30.5 PAX5 MS4A1 MIR155 IRF4
9 cll/sll 30.4 ZAP70 PAX5 CCND1
10 diffuse large b-cell lymphoma 30.3 PAX5 MYD88 MIR155 IRF4 CXCR4 CCND1
11 plasmacytoma 30.1 PAX5 IRF4 IGH CXCL12 CCND1
12 plasma cell neoplasm 30.1 PAX5 IRF4 CD40LG CCND1
13 myeloma, multiple 29.9 PAX5 IRF4 CXCR4 CXCL12 CD40LG CCND1
14 monoclonal gammopathy of uncertain significance 29.8 MYD88 MAG IRF4 CD40LG CCND1
15 follicular lymphoma 29.8 PAX5 MS4A1 MIR155 IRF4 IGH CCND1
16 mature b-cell neoplasm 29.7 PAX5 MIR155 IRF4 CD40LG CCND1
17 b-cell lymphoma 29.6 ZAP70 PAX5 MYD88 MS4A1 MIR155 IRF4
18 burkitt lymphoma 29.5 PAX5 MS4A1 MIR155 IRF4 CD40LG CCND1
19 lymphoma, mucosa-associated lymphoid type 29.4 ZAP70 PAX5 MYD88 IRF4 IGH CD40LG
20 mantle cell lymphoma 29.3 PAX5 MS4A1 MIR155 IGH CXCR4 CD40LG
21 lymphoma, non-hodgkin, familial 29.2 PAX5 MYD88 MS4A1 MIR155 IRF4 IGH
22 leukemia, acute lymphoblastic 29.0 ZAP70 PAX5 MIR155 IRF4 IGH CXCR4
23 leukemia, chronic lymphocytic 28.5 ZAP70 PAX5 MYD88 MS4A1 MIR542 MIR155
24 lymphoplasmacytic lymphoma without igm production 12.4
25 monoclonal paraproteinemia 10.5 PAX5 CD40LG
26 aids dementia complex 10.5 CXCR4 CXCL12
27 intraocular lymphoma 10.4 PAX5 CXCR4 CXCL12
28 plasma protein metabolism disease 10.4 MYD88 CXCR4 CD40LG
29 osteosclerotic myeloma 10.4 MAG CD40LG
30 mental retardation, autosomal dominant 40 10.4 CXCR4 CXCL12
31 chronic polyneuropathy 10.4 MAG CD40LG
32 nodular lymphocyte predominant hodgkin lymphoma 10.4 PAX5 CCND1
33 agammaglobulinemia, x-linked 10.4 CXCR4 CXCL12 CD40LG
34 whim syndrome 10.4 CXCR4 CXCL12 ACKR3
35 asymmetric motor neuropathy 10.4 MAG CD40LG
36 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 MYD88 IRF4
37 primary central nervous system lymphoma 10.4 PAX5 MYD88
38 cerebral lymphoma 10.4 MAG CD40LG
39 spastic monoplegia 10.4 HAS1 CD40LG
40 autoimmune peripheral neuropathy 10.3 MAG CD40LG
41 breast lymphoma 10.3 PAX5 IRF4
42 tracheal lymphoma 10.3 PAX5 CCND1
43 splenomegaly 10.3
44 central nervous system lymphoma 10.3 PAX5 MYD88 CXCR4 CXCL12
45 mononeuritis of upper limb and mononeuritis multiplex 10.3 MAG CD40LG
46 polyradiculoneuropathy 10.3 MAG CXCR4 CXCL12
47 primary cutaneous b-cell lymphoma 10.3 PAX5 MS4A1
48 primary bacterial infectious disease 10.3 MYD88 MIR155 CD40LG
49 alpha chain disease 10.3 CD40LG CCND1
50 mononeuritis multiplex 10.3 MAG CD40LG

Graphical network of the top 20 diseases related to Lymphoplasmacytic Lymphoma:

Diseases related to Lymphoplasmacytic Lymphoma

Symptoms & Phenotypes for Lymphoplasmacytic Lymphoma

MGI Mouse Phenotypes related to Lymphoplasmacytic Lymphoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACKR3 CCND1 CD40LG CXCL12 CXCR4 IRF4
2 immune system MP:0005387 9.36 ACKR3 CCND1 CD40LG CXCL12 CXCR4 IRF4

Drugs & Therapeutics for Lymphoplasmacytic Lymphoma

Drugs for Lymphoplasmacytic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Lenograstim Approved, Investigational Phase 4 135968-09-1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
4 Alkylating Agents Phase 4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Chlorambucil Approved Phase 3 305-03-3 2708
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
Tazobactam Approved Phase 3 89786-04-9 123630
Vancomycin Approved Phase 3 1404-90-6 14969 441141
Piperacillin Approved Phase 3 66258-76-2 43672
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
Idelalisib Approved Phase 3 870281-82-6
24 Anesthetics Phase 3
25 Anesthetics, General Phase 3
26 Anesthetics, Intravenous Phase 3
27 Anesthetics, Dissociative Phase 3
28 Anti-Bacterial Agents Phase 3
29 Antifungal Agents Phase 3
30 Neurotransmitter Agents Phase 3
31 Etoposide phosphate Phase 2, Phase 3
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
33 Antiparasitic Agents Phase 3
34 Antiprotozoal Agents Phase 3
35 Analgesics Phase 3
36 Hematinics Phase 3
37 Analgesics, Opioid Phase 3
38 Excitatory Amino Acid Antagonists Phase 3
39 Respiratory System Agents Phase 3
40 Antitussive Agents Phase 3
41 Narcotics Phase 3
42 Epoetin alfa Phase 3 113427-24-0
43 Piperacillin, Tazobactam Drug Combination Phase 3
44 ferric gluconate Phase 3
45 Iron Supplement Phase 3
46 Amebicides Phase 3
47 Liposomal amphotericin B Phase 3
protease inhibitors Phase 3
49 HIV Protease Inhibitors Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 430)
# Name Status NCT ID Phase Drugs
1 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
2 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
3 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
4 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Recruiting NCT04042376 Phase 4 Ibrutinib
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
8 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
9 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
10 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
11 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
12 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
13 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
14 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
15 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
16 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
17 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
18 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
19 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
20 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
22 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
23 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
24 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
25 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 PCI-32765 (Ibrutinib)
26 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Not yet recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
27 Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) Not yet recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
28 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
29 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
30 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
31 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
32 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
33 Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas Unknown status NCT00927797 Phase 2 Cyclophosphamide, Pentostatin, Rituximab
34 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
35 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
36 A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy Unknown status NCT01658241 Phase 2 panobinostat
37 Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
38 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
39 A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia Completed NCT02302469 Phase 1, Phase 2 Revlimid
40 Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00142181 Phase 2 Campath-1H
41 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed NCT00422656 Phase 2 Perifosine
42 Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00020800 Phase 2 fludarabine phosphate
43 A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy Completed NCT00784927 Phase 2 cyclophosphamide;dexamethasone;lenalidomide
44 Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Completed NCT00142116 Phase 2 Thalidomide;Rituximab
45 Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas Completed NCT01076543 Phase 1, Phase 2 Lenalidomide;Temsirolimus
46 Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Completed NCT01416428 Phase 1, Phase 2 oprozomib
47 UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia Completed NCT00083707 Phase 2 Thalidomide
48 A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia Completed NCT00811733 Phase 2
49 A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia Completed NCT01109069 Phase 2 PCI-32765
50 An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy Completed NCT01647971 Phase 1, Phase 2 Ublituximab

Search NIH Clinical Center for Lymphoplasmacytic Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoplasmacytic Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoplasmacytic Lymphoma

Anatomical Context for Lymphoplasmacytic Lymphoma

MalaCards organs/tissues related to Lymphoplasmacytic Lymphoma:

B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Spleen, Liver

Publications for Lymphoplasmacytic Lymphoma

Articles related to Lymphoplasmacytic Lymphoma:

(show top 50) (show all 894)
# Title Authors PMID Year
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. 46
19074725 2009
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. 54 61
18815290 2008
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. 54 61
18537966 2008
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. 61 54
18452095 2008
Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. 61 54
16960805 2006
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. 54 61
16983704 2006
Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma. 54 61
16956840 2006
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique. 54 61
16280661 2005
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. 54 61
16231851 2005
How we treat Waldenström's macroglobulinemia. 61 54
15642678 2005
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. 61 54
15493038 2004
Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. 61 54
14764523 2004
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 61 54
15133473 2004
Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). 61 54
15116325 2004
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. 61 54
12720146 2003
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. 54 61
12351413 2002
Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). 54 61
10350329 1999
Peripheral neuropathy in IgM monoclonal gammopathy and Wäldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. 54 61
7504399 1994
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. 61
31992103 2020
Waldenstrom's macroglobulinemia in the era of immunotherapy. 61
31960730 2020
Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. 61
32090327 2020
Neoplastic Cutaneous Infiltration by Lymphoplasmacytic Lymphoma in a Patient with Waldenström's Macroglobulinemia. 61
32553661 2020
Tirabrutinib: First Approval. 61
32382949 2020
Hematologist-Level Classification of Mature B-Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data. 61
32519455 2020
Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases. 61
32220598 2020
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. 61
32558607 2020
Clinical Reasoning: Multifocal neuropathies in a patient with Waldenstrom macroglobulinemia and prior borreliosis. 61
32527969 2020
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia. 61
32532610 2020
Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia. 61
31858758 2020
Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report. 61
32384445 2020
Exclusive B-cell phenotype of primary prostatic lymphomas: a potential role of chronic prostatitis. 61
31825109 2020
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. 61
32249238 2020
Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy. 61
32033929 2020
An unusual case of cutaneous Waldenstrom macroglobulinemia with the MYD88 L265P mutation. 61
32335928 2020
Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report. 61
32323419 2020
Waldenstrom's Macroglobulinemia: A case report. 61
32509689 2020
Lymphoplasmacytic lymphoma infiltrating both lacrimal glands in a patient with Waldenström's macroglobulinemia. 61
32016162 2020
Two-sided femoral Campylobacter jejuni osteomyelitis in a patient with acquired hypogammaglobulinemia: a case report. 61
32143636 2020
Maculopathy in Patients with Monoclonal Gammopathy of Undetermined Significance. 61
31753810 2020
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience. 61
31852014 2020
A man in his 70s with neurological symptoms and progressive pain during cancer therapy. 61
32026856 2020
Crystal-storing histiocytosis leading to the identification of IgG-kappa secreting lymphoplasmacytic lymphoma with crystalline nephropathy. 61
31883675 2020
Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis. 61
31767130 2020
A Case of a Lymphoplasmacytic Lymphoma with Trisomy 12 in the Lymphoid Population and Deletion 13q in the Unstimulated Cell Culture. 61
32161185 2020
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. 61
31980558 2020
Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature. 61
31862225 2020
JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. 61
31432632 2020
Treatment modalities of non-Hodgkin lymphoma patients over 65 years of age: A two-center experience. 61
30924740 2020
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. 61
32158088 2020
Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. 61
32509586 2020

Variations for Lymphoplasmacytic Lymphoma

Cosmic variations for Lymphoplasmacytic Lymphoma:

# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143780282 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 0

Expression for Lymphoplasmacytic Lymphoma

Search GEO for disease gene expression data for Lymphoplasmacytic Lymphoma.

Pathways for Lymphoplasmacytic Lymphoma

Pathways related to Lymphoplasmacytic Lymphoma according to KEGG:

# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.05 MIR494 MIR206 MIR155 CCND1
2 11.68 ZAP70 PAX5 MYD88 IRF4 CXCR4 CXCL12
3 11.27 ZAP70 MYD88 CXCL12 CD40LG
4 10.06 MIR206 MAG

GO Terms for Lymphoplasmacytic Lymphoma

Cellular components related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 MS4A1 CXCR4 CXCL12 CD40LG ACKR3

Biological processes related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.88 MIR542 MIR494 MIR206 MIR184 MIR155
2 immune response GO:0006955 9.72 ZAP70 CXCR4 CXCL12 CD40LG ACKR3
3 response to virus GO:0009615 9.7 MYD88 CXCR4 CXCL12
4 cell chemotaxis GO:0060326 9.61 CXCR4 CXCL12 ACKR3
5 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 9.51 CXCL12 ACKR3
6 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.49 CXCR4 CXCL12
7 detection of mechanical stimulus involved in sensory perception of pain GO:0050966 9.46 CXCR4 CXCL12
8 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.4 MYD88 MIR155
9 negative regulation of cell adhesion molecule production GO:0060354 9.37 MIR206 MIR155
10 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.33 MIR494 MIR206 MIR155
11 telencephalon cell migration GO:0022029 9.26 CXCR4 CXCL12
12 positive regulation of mesenchymal stem cell migration GO:1905322 8.96 CXCR4 ACKR3
13 response to ultrasound GO:1990478 8.62 CXCR4 CXCL12

Molecular functions related to Lymphoplasmacytic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-X-C chemokine receptor activity GO:0016494 8.62 CXCR4 ACKR3

Sources for Lymphoplasmacytic Lymphoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....